Efficacy and Safety Profile of Autologous Blood Versus Talc Pleurodesis for Malignant Pleural Effusio

Not Applicable

Completed

• Conditions: Symptomatic malignant pleural effusion patients; Pleurodesis, Autologous blood, Talc, Malignant pleural effusion, MPE, Efficacy

• Registration Number: TCTR20150717001
• Lead Sponsor: Human Research Ethic Committee

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-07-17
• Study Completion: 2016-07-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

- Patients 18 years of age and older
- Symptomatic MPE (cytologically or histologically confirmed) patients
- Life expectancy of more than 3 months
- Good lung expansion after drainage of pleural fluid with approximation of visceral and parietal pleura
- Agreement to receive chemical pleurodesis for treatment of MPE

Exclusion Criteria

- Any pleural or systemic infection
- Hemodynamic instability
- Hemothorax (pleural fluid over serum hematocrit > 50%)
- Serum hematocrit < 25%
- Chylothorax
- Combination of causes of pleural effusion
- History of talc or lidocaine allergy
- Chest X ray showing trapped lung after chest tube drainage
- Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the efficacy of autologous blood pleurodesis Versus Talc pleurodesis at 1 month Chest radiograph

Secondary Outcome Measures

Name	Time	Method
To evaluate safety of autologous blood pleurodesis Versus Talc pleurodesis upto 1 week Pain score, fever